CRA was retained by the claimant in an arbitration regarding the breach of a license agreement relating to pharmaceutical manufacturing technology. In addition to quantifying damages, the CRA team also provided opinions relating to the value of market exclusivity for pharmaceuticals and the relative value of the licensed patented and non-patented intellectual property at issue in the case. Dr. Sean Sheridan submitted two expert reports and provided testimony in deposition and at the arbitration hearing.
Recent trends in Rule 702 decisions – 2024
In this CRA Insights, we update the Rule 702 decision trends in last year’s Insights with 2023 data.[1] We also provide descriptions of four specific...